Purchase this article with an account.
G. F. Schwartz, J. Fain, J. Mardekian, S. Kotak; 1-Year Incidence of Dry Eye in Open-Angle Glaucoma (OAG) and Ocular Hypertension (OH) Patients Treated With Latanoprost (LAT) or Travoprost-Z (TRAV-Z). Invest. Ophthalmol. Vis. Sci. 2009;50(13):4653.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To compare the 1-year incidence rates of dry eye in OAG and OH patients newly treated with LAT or TRAV-Z.
This retrospective analysis of information in the Pharmetrics database included patients with any OAG or OH diagnosis within 3 months of the first (index) prescription for LAT or TRAV-Z monotherapy. Patients were excluded if they had a LAT or TRAV-Z prescription within 6 months pre-index or if they had a diagnosis of dry eye (ICD-9-CM codes: 370.33, 375.15, 710.2; CPT: 68760, 68761) within 3 months pre-index. Time to incidence of dry eye during the first year post-index period was estimated using a composite endpoint: a post-index dry eye-related diagnosis identified by ICD-9-CM code OR a post-index prescription for Restasis.
2996 patients were identified on index monotherapy (LAT, 2348; TRAV-Z, 648). The mean age was ≈65 years in both groups. Over 1 year, 5.6% (132/2348) of LAT and 7.8% (51/648) of TRAV-Z patients were identified with dry eye or were prescribed Restasis (P=0.0367; log-rank test).
The retrospective analysis of a large prescription database revealed that OAG and OH patients newly treated with LAT monotherapy were statistically significantly less likely to develop dry eye during the first year post-index period versus newly treated TRAV-Z patients.
This PDF is available to Subscribers Only